THERANOSTIC METHOD BASED ON THE DETECTION OF HER2-HER2 DIMERS

摘要

The present invention relates to an ex vivo method for determining the susceptibility of a patient suffering from cancer to respond to a therapeutic treatment based on the administration of an antibody specific for the HER2 protein, this method comprising the quantification of HER2-HER2 dimers in a tissue sample from said patient using the FRET technique. The invention also relates to a kit of reagents for implementing this method.